Levi & Korsinsky Announces Sarepta Therapeutics Class Action Investigation; SRPT Lawsuit

Class Action Reports

Levi & Korsinsky Announces Sarepta Therapeutics Class Action Investigation; SRPT Lawsuit

Levi & Korsinsky, LLP

September 24, 2019

Levi & Korsinsky, LLP announces that a SRPT class action lawsuit has been commenced on behalf of investors who purchased Sarepta Therapeutics, Inc. (SRPT) securities between September 6, 2017 and August 19, 2019. For more on the Sarepta Therapeutics Class Action please contact us today.

According to the Sarepta Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) golodirsen, Sarepta’s drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (2) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (3) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE SRPT CLASS ACTION, VISIT: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?wire=3

If you suffered a loss in Sarepta Therapeutics you have until October 29, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

 

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com